{"id":"NCT01554618","sponsor":"AstraZeneca","briefTitle":"Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes","officialTitle":"A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12-02","primaryCompletion":"2020-05-06","completion":"2021-05-05","firstPosted":"2012-03-15","resultsPosted":"2020-12-03","lastUpdate":"2021-11-30"},"enrollment":84,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Children and Adolescent With Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Exenatide Once Weekly","otherNames":["BYDUREON"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"EQW","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period)","timeFrame":"Baseline (Week 0) and Week 24","effectByArm":[{"arm":"Controlled Assessment Period - Exenatide","deltaMin":-0.36,"sd":0.184},{"arm":"Controlled Assessment Period - Placebo","deltaMin":0.49,"sd":0.273}],"pValues":[{"comp":"OG001","p":"0.012"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States","Bulgaria","Hungary","Israel","Kuwait","Mexico","Ukraine"]},"refs":{"pmids":["35679098"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5551C00002&amp;attachmentIdentifier=0bc86ca3-7a75-4e8f-a9ad-4e5eecc559f2&amp;fileName=D5551C00002_SAP_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5551C00002&amp;attachmentIdentifier=db17e8c6-3fcb-4682-a3b7-55f643581f58&amp;fileName=D5551C00002_CSP_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5551C00002&amp;attachmentIdentifier=32faa63c-a8de-4c1a-9aa4-6a3c46170eef&amp;fileName=D5551C00002_CSR_synopsis.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":59},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Cough"]}}